Wir sind mit live! Mehr erfahren

Alamar Biosciences

ALMR

Börsenwert 1,75 Mrd. $

25,28 USD

-2,14

7,8 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

25,28

0,00

0 %

1 Tag

-7,8 %

5 Tage

0,84 %

1 Monat

-13,96 %

3 Monate

1,32 %

6 Monate

14,91 %

Seit Jahresbeginn

14,91 %

1 Jahr

14,91 %

5 Jahre

14,91 %

10 Jahre

14,91 %

Profil: Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.

Gesundheitswesen Medizintechnik

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 33,3 %

Neutral 66,7 %

Negativ 0 %

Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026

FREMONT, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the third quarter 2026 after market close on Tuesday, November 3, 2026.

Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026

Alamar: The Consumables Flywheel Is Just Getting Started

Alamar Biosciences is rated a buy, targeting a recurring consumables-driven model with expansion into clinical diagnostics. 2Q26 revenue surged 82% YoY to $29.4M, with consumables up 147% and now exceeding half of total revenue. Gross margin improved to 60% on manufacturing efficiencies and consumables mix, but high operating expenses maintain losses amid aggressive investment.

Alamar: The Consumables Flywheel Is Just Getting Started

Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team

Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer

Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team

Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment

Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab

Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment

Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.

Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

Alamar Biosciences: Promising But Expensive Proteomics Growth

Alamar Biosciences' ARGO instruments automate NULISA assays. This creates a platform that can convert placements into recurring consumables' demand. I concede that ALMR's broader disease panels and sampling could also deepen the utilization of its platform and expand its long-term TAM even into diagnostics. The good news is that consumables are growing faster than instruments. But we need to see if this will be long-term profitable growth as the installed base expands.

Alamar Biosciences: Promising But Expensive Proteomics Growth

Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument

Alamar Biosciences is building a content-driven proteomics platform, with accelerating consumables revenue and expanding biomarker panels driving long-term growth. Q2 2026 revenue grew 82% YoY to $29.4M, with consumables sales up 147% and gross margin rising to 60%, highlighting improving revenue quality and operational leverage potential. ALMR's installed base enables capital-efficient expansion, with new assays deployable across existing instruments, creating workflow stickiness and recurring revenue opportunities.

Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument

Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum

Alamar Biosciences Inc. (NASDAQ:ALMR) shares are trading higher on Tuesday as the company is expanding its global partnership with the Alzheimer's Disease Data Initiative and Gates Ventures.

Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum

Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript

Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript

Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt